PBS listing of dabigatran in jeopardy

The listing of new oral anticoagulants, such as dabigatran, on the PBS is in jeopardy following the release of  a long-awaited and much anticipated Federal Government-led review of the drugs.

The 155-page report by Professor Lloyd Sansom found that the cost-effectiveness and safety of the medications were still in doubt following fresh data on how dabigatran works in real life settings, compared with clinical trial evidence.